End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: A systematic review and meta-analysis

Clinical Cancer Research

Volumn 19, Issue 23, 2013, Pages 6566-6577

  Pyo, Junhee ^a   Kim, Kyung Won ^b,c,d   Jacene, Heather A ^b,c   Sakellis, Christopher G ^b,c   Brown, Jennifer R ^b   Van Den Abbeele, Annick D ^b,c   Behrens, C ^a,d  

^a TUFTS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER REGRESSION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLICULAR LYMPHOMA; HUMAN; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOM EFFECTS MODEL; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, FOLLICULAR; PATIENT OUTCOME ASSESSMENT; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84890264983     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1511     Document Type: Review

References (35)

1. Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival-A study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol 2010;28:822-9.
2. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8.
3. Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before highdose chemotherapy for lymphoma: A systematic review and metaanalysis. Oncologist 2010;15:750-9.
4. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med 2008;49:13-21.
5. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004;5:531-40.
6. Ansell SM, Armitage JO. Positron emission tomographic scans in lymphoma: convention and controversy. Mayo Clin Proc 2012;87:571-80.
7. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
8. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18) F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010;51:25-30.
9. Wohrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006;17:780-4.
10. Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006;107:175-83.
11. National Comprehensive Cancer Network practice guidelines 2013. Non-Hodgkin's Lymphomas Version 1. [cited 2012 May 15]. Available from: www.nccn.org/professionals/physician-gls/pdf/nhl.pdf
12. Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A. Report on the 4th international workshop on positron emission tomography in lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma 2013 Jun. 14. [Epub ahead of print].
13. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
14. Bishu S, Quigley JM, Bishu SR, Olsasky SM, Stem RA, Shostrom VK, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxyglucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 2007;48:1548-55.
15. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOE-LAMS. J Clin Oncol 2012;30:4317-22.
16. Janikova A, Bolcak K, Pavlik T, Mayer J, Kral Z. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicularlymphoma: the end of a dilemma? Clin Lymphoma Myeloma 2008;8:287-93.
17. Le Dortz L, De Guibert S, Bayat S, Devillers A, Houot R, Rolland Y, et al. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 2010;37:2307-14.
18. Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F, et al. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y-90: multicentric study. Ann Oncol 2010;21:1877-83.
19. Lopci E, Zanoni L, Chiti A, Fonti C, Santi I, Zinzani PL, et al. FDG PET/CT predictive role in follicular lymphoma. Eur J Nucl Med Mol Imaging 2012;39:864-71.
20. Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011;29:3194-200.
21. Zinzani PL, Musuraca G, Alinari L, Fanti S, Tani M, Stefoni V, et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 2007;7:291-5.
22. Oldenhuis CN, Oosting SF, Gietema JA, De Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008;44:946-53.
23. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into metaanalysis. Trials 2007;8:16.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
26. Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781-7.
27. Tateishi U, Tatsumi M, Terauchi T, Ishizawa K, Ogura M, Tobinai K. Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study. Cancer Sci 2011;102:414-8.
28. Storto G, De Renzo A, Pellegrino T, Perna F, De Falco T, Erra P, et al. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-hodgkin lymphoma1. Radiology 2010;254:245-52.
29. Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR, et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008;14:7088-94.
30. Imataki O, Tamai Y, Yokoe K, Furukawa T, Kawakami K. The utility of FDG-PET for managing patients with malignant lymphoma: analysis of data from a single cancer center. Int Med 2009;48:1509-13.
31. Grgic A, Nestle U, Scheidhauer K, Puskas C, Ballek E, Hohloch K, et al. Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphoma. Nuklearmedizin 2011;50:39-47.
32. Lopci E, Santi I, Tani M, Maffione AM, Montini G, Castellucci P, et al. FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. Q J Nucl Med Mol Imaging 2010;54:436-41.
33. Zinzani PL, Marchetti M, Billio A, Barosi G, Carella AM, Lazzarino M, et al. SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. Am J Hematol 2013;88:185-92.
34. Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 2009;50:8-17.
35. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.